APLS - Apellis Pharmaceuticals Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Select Current Price & Safety Score Price: 41.03 USD StockBonds Safety Grade: F Altman Z-Score (Bankruptcy Risk): 3.24 StockBond Score: 0.00 Company Description Apellis Pharmaceuticals Inc a commercialstage biopharmaceutical company focuses on the discovery development and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases The companys lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy GA in agerelated macular degeneration and paroxysmal nocturnal hemoglobinuria PNH diseases It also develops EMPAVELI systemic pegcetacoplan for the treatment of cold agglutinin disease CAD and hematopoietic stem cell transplantationassociated thrombotic microangiopathy HSCTTMA in hematology C3 glomerulopathy C3G and immune complex membranoproliferative glomerulonephritis ICMPGN in nephrology and amyotrophic lateral sclerosis ALS in neurology In addition the company develops APL2006 a bispecific C3 and VEGF inhibitor for treating complementmediated disorders APL1030 a C3 inhibitor for the treatment of multiple neurodegenerative diseases and the combination of EMPAVELI and a small interfering RNA or siRNA for reducing the production of C3 proteins by the liver It has a collaboration and license agreement with Swedish Orphan Biovitrum AB publ to codevelop pegcetacoplan and a research collaboration with Beam Therapeutics Inc focused on the use of Beams base editing technology to discover new treatments for complementdriven diseases Apellis Pharmaceuticals Inc was incorporated in 2009 and is based in Waltham Massachusetts